Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,936.00INR
20 Jan 2017
Change (% chg)

Rs-3.40 (-0.12%)
Prev Close
Rs2,939.40
Open
Rs2,929.00
Day's High
Rs2,958.90
Day's Low
Rs2,924.55
Volume
14,200
Avg. Vol
25,571
52-wk High
Rs3,689.00
52-wk Low
Rs2,750.00

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.16
Market Cap(Mil.): Rs503,247.19
Shares Outstanding(Mil.): 170.74
Dividend: 20.00
Yield (%): 0.68

Financials

  REDY.BO Industry Sector
P/E (TTM): -- 29.51 30.38
EPS (TTM): -- -- --
ROI: -- 15.44 14.86
ROE: -- 16.62 16.28

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

12 Jan 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

11 Nov 2016

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance

09 Nov 2016

BUZZ-India's drugmakers decline on worries about possible U.S. probe

** Shares of India's drugmakers fall, sending Nifty Pharma index down as much as 4.5 pct to lowest since June 24

04 Nov 2016

BRIEF-Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters

* Exec says have addressed all FDA requirements on warning letters

25 Oct 2016

BRIEF-Dr.Reddy's Laboratories Sept-qtr consol profit falls 60 pct

* Co to continue to focus on launching new products in generic business

25 Oct 2016

BRIEF-Dr. Reddy's Labs launches Aripiprazole tablets, USP tablets in U.S. market

* Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. market Source text for Eikon: Further company coverage: (Bengaluru newsroom)

13 Oct 2016

BRIEF-Dr.Reddy's launches Lamotrigine Orally Disintegrating tablets in U.S

* Announces the launch of Lamotrigine Orally Disintegrating tablets in the U.S. market Source text: http://bit.ly/2dFkVt2 Further company coverage:

10 Oct 2016

BRIEF-Dr.Reddy's Labs announces entry into Columbia

* Announces entry into Columbia Source text: http://bit.ly/2dzOUiD Further company coverage: (Bengaluru newsroom)

07 Oct 2016

BRIEF-DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets, USP (sr) in U.S. market

* Launch of bupropion hcl extended-release tablets, usp (sr) in u.s. Market Source text for Eikon: Further company coverage:

02 Sep 2016

Earnings vs. Estimates